You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Interferon beta-1a - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for interferon beta-1a
Recent Clinical Trials for interferon beta-1a

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of SouthamptonPhase 2
George Washington UniversityPhase 2
University of North Carolina, Chapel HillPhase 2

See all interferon beta-1a clinical trials

Recent Litigation for interferon beta-1a

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Merck KGaA v. Hopewell Pharma Ventures, Inc.2022-10-17
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28

See all interferon beta-1a litigation

PTAB Litigation
PetitionerDate
Hopewell Pharma Ventures, Inc. et al.2023-02-10

See all interferon beta-1a litigation

Pharmacology for interferon beta-1a
Established Pharmacologic ClassInterferon beta
Chemical StructureInterferon-beta
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for interferon beta-1a Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for interferon beta-1a Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for interferon beta-1a Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Interferon Beta-1a

Market Size and Growth Projections

The global interferon beta drugs market, which includes interferon beta-1a, is experiencing significant growth driven by several key factors. As of 2023, the market size for interferon beta drugs is valued at USD 3.22 billion and is projected to reach USD 4.66 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period of 2024-2031[1].

Another projection suggests that the global beta interferon market will reach a value of USD 4.8 billion by 2033, indicating a steady and robust growth trajectory[3].

Regional Market Performance

The market for interferon beta drugs is geographically diverse, with different regions contributing significantly to its growth.

  • Europe: This region dominated the market in 2023 and is expected to continue its strong performance due to the presence of major players such as Bayer, Novartis, and Merck KGaA. The approval of new drugs, like BIOCAD's BCD-033 in Russia, further supports this growth[1].
  • North America: This region is also a significant contributor, driven by high healthcare expenditure and the prevalence of multiple sclerosis (MS). North America is leading the interferon beta drugs market with the maximum revenue share[4].
  • Asia-Pacific: This region is exhibiting the fastest growth rate, driven by increasing healthcare expenditure and rising awareness about MS. China, in particular, is expected to see a CAGR of 5% over the next 10 years[3][4].

Key Drivers of Growth

Several factors are driving the growth of the interferon beta drugs market:

  • Increasing Prevalence of Multiple Sclerosis: The rising incidence of MS is a primary factor boosting the demand for interferon beta drugs. MS is a chronic disease that affects the central nervous system, and interferon beta-1a is a key treatment option[4].
  • Government Initiatives and Healthcare Expenditure: Government initiatives aimed at improving healthcare infrastructure and providing financial assistance for chronic disease treatments are significant drivers. Increasing healthcare expenditure in both developed and developing countries enables more patients to afford these expensive treatments[1].
  • Research and Development: Continuous R&D in MS treatments is another trend driving the market forward. New formulations and delivery methods, such as peginterferon beta-1a, are improving treatment outcomes and cost-effectiveness[2][4].

Cost-Effectiveness and Clinical Outcomes

Studies have shown that interferon beta-1a, particularly in its pegylated form (peginterferon beta-1a), offers improved clinical outcomes at reduced costs compared to other disease-modifying therapies (DMTs).

  • A cost-effectiveness analysis revealed that peginterferon beta-1a is more effective and less costly than interferon beta-1a 44 mcg and glatiramer acetate 20 mg over a 10-year period. This analysis indicated cost savings of $22,070 and $19,163, respectively, along with additional quality-adjusted life years (QALYs)[2].

Product Types and Administration Methods

The market for interferon beta drugs is segmented by product type and source of administration:

  • Product Types: Interferon beta-1a is one of the significant product types, used to treat various forms of MS. Other notable products include Avonex, Extavia, Betaseron, Plegridy, and Rebif[4].
  • Source of Administration: These drugs can be administered subcutaneously, intravenously, or intramuscularly. Subcutaneous administration is particularly common and has shown significant market share and growth potential[4].

End-User Segmentation

The end-user segmentation of the interferon beta drugs market includes:

  • Hospitals and Pharmacies: Hospitals and pharmacies are the primary end-users, with hospitals' pharmacies earning the highest revenue. Retail pharmacies also account for a significant share, while online pharmacies are expected to grow rapidly in the future[4].

Challenges and Barriers

Despite the growth, there are challenges that the market faces:

  • High Cost of Treatment: The high cost of interferon beta drugs can act as a significant barrier to access, limiting market growth. This is particularly true in regions with lower healthcare expenditure and less financial assistance for chronic disease treatments[1].

Long-Term Efficacy and Adherence

Interferon beta-1a has been in continuous clinical use for over 25 years, demonstrating long-term efficacy in treating MS.

  • Studies such as the PRISMS trial and its long-term extension have shown that interferon beta-1a subcutaneously reduces the risk of disease progression over prolonged periods. Higher cumulative doses and longer treatment adherence are associated with better outcomes, including lower relapse rates and slower disability progression[5].

Key Takeaways

  • The global interferon beta drugs market is projected to grow significantly, driven by increasing MS prevalence, government initiatives, and R&D.
  • Europe and North America are leading regions, with the Asia-Pacific region showing the fastest growth.
  • Interferon beta-1a, especially in its pegylated form, offers improved cost-effectiveness and clinical outcomes.
  • High treatment costs remain a barrier, but long-term efficacy and adherence support the market's growth.

Frequently Asked Questions (FAQs)

Q: What is the current market size of the interferon beta drugs market? A: As of 2023, the market size for interferon beta drugs is valued at USD 3.22 billion[1].

Q: What is the projected growth rate of the interferon beta drugs market? A: The market is expected to grow at a CAGR of 4.9% from 2024 to 2031[1].

Q: Which regions are leading the interferon beta drugs market? A: Europe and North America are the leading regions, with the Asia-Pacific region showing the fastest growth[1][4].

Q: What are the key drivers of the interferon beta drugs market? A: Key drivers include the increasing prevalence of MS, government initiatives, and rising healthcare expenditure[1][4].

Q: Is interferon beta-1a cost-effective compared to other treatments? A: Yes, studies have shown that peginterferon beta-1a is more effective and less costly than other DMTs over a long-term period[2].

Cited Sources

  1. InsightAce Analytic: Interferon Beta Drugs Market Analysis and Forecast 2024-2031.
  2. PubMed: Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate.
  3. GlobeNewswire: Beta Interferon Drugs Sales Expected to Reach USD 4.8 Billion by 2033.
  4. Acumen Research and Consulting: Interferon Beta Drugs Market Size, Share and Analysis | Forecast.
  5. Taylor & Francis Online: Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.